

Antibiogramme 2021 L'Hôpital Riviera-Chablais

Doubles, defined as identical microorganism with identical resistance profile isolated from the same patient within 365 days, are not included in the analysis.

Antibiotikum	Enterococcus faecalis		Enterococcus faecium		Staphylococcus aureus		Staphylococcus, koagulase-negativ		Streptococcus pneumoniae	
	% S	n	% S	n	% S	n	% S	n	% S	n
Penicillin									90.0%	10
Ampicillin	100%	200	43.2%	44					100%	6
Amoxicillin-clavulanic acid	100%	200	43.2%	44	91.9%	285	60.9%	256	100%	6
Ceftriaxon									100%	5
Imipenem					91.9%	285	60.9%	256	100%	6
Gentamicin	84.9%	199	59.1%	44	97.6%	287	77.3%	256		
Trimethoprim-sulfamethoxazole					92.6%	285	84.4%	256	84.6%	13
Clindamycin					80.7%	285	66.4%	256		
Erythromycin					77.5%	285	53.9%	256	84.6%	13
Teicoplanin	100%	200	93.2%	44	99.3%	285	100%	5		
Vancomycin	100%	199	93.2%	44	100%	285	100%	256	100%	13
Ciprofloxacin					93.4%	287	70.7%	256		
Levofloxacin					93.3%	285	70.3%	256	100%	13
Fusidic acid					94.8%	287	41.0%	256		
Rifampicin					98.9%	285	99.2%	256		

According to new EUCAST recommendations %S means percentage of isolates tested susceptible (S) or susceptible with increased dosing (I) against the specific antibiotic.

Antibiogramme 2021 L'Hôpital Riviera-Chablais

Doubles, defined as identical microorganism with identical resistance profile isolated from the same patient within 365 days, are not included in the analysis.

Antibiotikum	Achromobacter spp.		Acinetobacter spp.		Citrobacter freundii complex		Citrobacter koseri		Enterobacter cloacae-komplex		Enterobacter, other		Escherichia coli		Haemophilus influenzae		Hafnia species		Klebsiella aerogenes		
	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	
Penicillin																					
Amoxicillin					0.0%	39	0.0%	31	0.0%	133	0.0%	5	56.5%	1815			0.0%	8	0.0%	44	
Ampicillin														58.8%	34						
Amoxicillin-clavulanic acid					0.0%	41	100%	34	0.7%	134	0.0%	5	86.3%	1726	79.4%	34	0.0%	9	0.0%	44	
Piperacillin-tazobactam	100%	7			80.0%	40	100%	34	75.9%	133	60.0%	5	96.6%	1672			33.3%	9	81.8%	44	
Ceftriaxon					64.7%	17	100%	14	77.6%	49			89.8%	722	91.2%	34				86.7%	15
Ceftazidime					85.4%	41	100%	34	76.9%	134	60.0%	5	96.4%	1782			66.7%	9	81.8%	44	
Cefepime					100%	40	100%	34	95.5%	132	80.0%	5	97.6%	1761			100%	9	100%	42	
Ertapenem					100%	41	100%	34	94.0%	133	100%	5	99.8%	1816			88.9%	9	100%	44	
Imipenem	100%	7	100%	19	100%	17	100%	15	100%	51			100%	789						100%	15
Gentamicin			100%	19	90.2%	41	100%	34	94.0%	134	80.0%	5	91.7%	1816			100%	9	100%	44	
Tobramycin			100%	19																	
Amikacin			100%	19	97.5%	40	100%	33	99.2%	129	100%	5	98.9%	1745			100%	9	100%	43	
Trimethoprim-sulfamethoxazole	71.4%	7	94.7%	19	85.4%	41	100%	34	91.8%	134	80.0%	5	79.8%	1816	76.5%	34	100%	9	100%	44	
Erythromycin																					
Ciprofloxacin			84.2%	19	78.0%	41	100%	34	91.0%	134	80.0%	5	84.9%	1812	97.3%	37	100%	9	97.7%	44	
Levofloxacin			84.2%	19									75.8%	66							
Nitrofurantoin					95.0%	40	100%	34	95.5%	134	100%	5	98.6%	1816			100%	9	86.0%	43	
Fosfomycin					95.0%	40	100%	34	46.3%	134	60.0%	5	98.4%	1799			33.3%	9	81.4%	43	

According to new EUCAST recommendations %S means percentage of isolates tested susceptible (S) or susceptible with increased dosing (I) against the specific antibiotic.

Antibiogramme 2021 L'Hôpital Riviera-Chablais

Doubles, defined as identical microorganism with identical resistance profile isolated from the same patient within 365 days, are not included in the analysis.

Antibiotikum	Klebsiella oxytoca		Klebsiella pneumoniae complex		Moraxella catarrhalis		Morganella morganii		Proteus mirabilis		Proteus vulgaris		Providencia spp.		Pseudomonas aeruginosa		Salmonella spp.		Serratia marcescens		Stenotrophomonas maltophilia	
	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n	% S	n
Penicillin					10.0%	10																
Amoxicillin	0.0%	57	0.3%	342			0.0%	31	64.9%	154	0.0%	31	0.0%	5			88.9%	9	0.0%	20		
Ampicillin					10.0%	10																
Amoxicillin-clavulanic acid	94.7%	57	91.5%	329	100%	10	0.0%	31	81.1%	159	80.6%	31	0.0%	5			100%	9	0.0%	20		
Piperacillin-tazobactam	96.5%	57	87.9%	331			100%	31	100%	159	96.8%	31	100%	5	91.2%	182	100%	9	100%	20		
Ceftriaxon	100%	24	91.4%	128	90.0%	10	100%	10	100%	62	92.9%	14							100%	6		
Ceftazidime	100%	57	94.7%	340			90.3%	31	100%	159	100%	31	100%	5	96.2%	183	100%	9	100%	20	89.5%	19
Cefepime	100%	57	98.2%	338			100%	30	100%	159	100%	31	100%	5	97.8%	183	100%	9	100%	20		
Ertapenem	100%	57	99.4%	342			100%	31	98.8%	160	100%	31	100%	5			100%	9	100%	20		
Imipenem	100%	29	99.3%	138			100%	13	100%	70	100%	17			98.5%	65			100%	8		
Gentamicin	98.2%	57	96.8%	342			96.8%	31	88.8%	160	96.8%	31	100%	5			0.0%	9	95.0%	20		
Tobramycin															98.9%	183						
Amikacin	100%	52	100%	329			100%	29	100%	152	100%	28			98.9%	182	0.0%	9	0.0%	18		
Trimethoprim-sulfamethoxazole	96.5%	57	90.1%	342	100%	10	93.5%	31	72.5%	160	80.6%	31	100%	5			100%	9	95.0%	20	100%	19
Erythromycin					100%	10																
Ciprofloxacin	98.2%	57	90.4%	342	100%	10	93.5%	31	85.0%	160	100%	31	100%	5	86.9%	183	100%	9	100%	20		
Levofloxacin	100%	5	72.7%	11					100%	8					85.8%	183					89.5%	19
Nitrofurantoin	98.2%	57	88.1%	337			0.0%	31	0.0%	160	0.0%	31	0.0%	5			100%	9	0.0%	20		
Fosfomycin	77.2%	57	79.2%	337			0.0%	31	85.0%	160	74.2%	31	60.0%	5			100%	9	90.0%	20		

According to new EUCAST recommendations %S means percentage of isolates tested susceptible (S) or susceptible with increased dosing (I) against the specific antibiotic.